FDA Adverse Event Injury Summary report: N

PROMUS EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 2154547 · Received July 8, 2011

Report

Report Number
2024168-2011-04889
Event Type
Injury
Date Received
July 8, 2011
Date of Event
March 1, 2011
Report Date
June 14, 2011
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P070015
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
OH, US
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION. AT THIS POINT A WIRE DISSECTION WAS NOTED IN THE RIGHT POSTERIOR LATERAL AND THE PROCEDURE WAS TERMINATED. THE SUBJECT WAS DISCHARGED ON (B)(6) 2011 AND THE EVENTS AS REPORTED WERE RESOLVED WITH NO RESIDUAL EFFECTS. NO ADDITIONAL INFORMATION WAS PROVIDED. THE 2.5 X 12 MM PROMUS, 3.0 X 15 PROMUS, THE 3.0 X 28 MM PROMUS AND THE 3.5 X 28 MM PROMUS ARE BEING FILED UNDER SEPARATE MEDWATCH MFR NUMBERS. DIL CATH: SCIMED APEX, SCIMED NC QUANTUM APEX. GUIDE WIRE: SCIMED CHOICE EX SUPPORT, CHOICE FLOPPY. INFLATION: ENCORE 26. GUIDE CATH: 6 FR LAUNCHER, SHERPA. RHV: COPILOT. OTHER: PRONTO LP. STENT: PROMUS (3.0X15, 3.0X28, 3.5X28). YOU ARE RECEIVING THIS MDR REPORT FROM ABBOTT VASCULAR BECAUSE BOSTON SCIENTIFIC CORPORATION DISTRIBUTES PROMUS AS ITS OWN BRAND LABELING OF ABBOTT VASCULARS DRUG ELUTING STENT IN THE US. THERE WAS NO REPORTED PRODUCT DEFICIENCY. THE REPORTED ANGINA, EMBOLISM, ARRHYTHMIA (INCLUDING BRADYCARDIA), HYPOTENSION AND OCCLUSION ARE LISTED IN THE PROMUS INSTRUCTIONS FOR USE AS KNOWN ADVERSE EVENTS ASSOCIATED WITH CORONARY STENTING. IT WAS REPORTED THAT THE PROMUS STENT WAS IMPLANTED FOR TREATMENT OF AN 80% RE-STENOSED PROMUS STENT. IT SHOULD BE NOTED THAT THE PROMUS EVEROLIMUS-ELUTING CORONARY STENT SYSTEM (PROMUS STENT) IS INDICATED FOR IMPROVING CORONARY LUMINAL DIAMETER IN PATIENTS WITH SYMPTOMATIC HEART DISEASE DUE TO DE NOVO NATIVE CORONARY ARTERY LESIONS (LENGTH LESS THAN OR EQUAL TO 28 MM) WITH REFERENCE VESSEL DIAMETERS OF 2.5 MM TO 4.25 MM. THE IMPLANTATION OF THE STENT TO TREAT IN-STENT RESTENOSIS DOES NOT APPEAR TO HAVE DIRECTLY CAUSED OR CONTRIBUTED TO THE REPORTED PATIENT EFFECTS. ALTHOUGH A CONCLUSIVE CAUSE FOR THE REPORTED PATIENT EFFECT, AND THE RELATIONSHIP TO THE PRODUCT, IF ANY, COULD NOT BE DETERMINED, THERE IS NO INDICATION OF A PRODUCT QUALITY DEFICIENCY WITH RESPECT TO MANUFACTURING, DESIGN OR LABELING THE TREATMENT APPEARS TO BE RELATED TO THE OPERATIONAL CONTEXT OF THE PROCEDURE.

Description of Event or Problem · 1

IT WAS REPORTED THAT THE SUBJECT WAS RANDOMIZED INTO THE PLATINUM WH STUDY ON (B)(6) 2009. THE TARGET LESION WAS LOCATED IN THE MID LEFT ANTERIOR DESCENDING ARTERY WITH A 90% STENOSIS. THE TARGET LESION WAS TREATED WITH PRE-DILATATION, AND PLACEMENT OF A 2.5 X 12 MM STUDY STENT, AND POST-DILATATION WITH 19% RESIDUAL STENOSIS. THE SUBJECT WAS DISCHARGED ON (B)(6) 2009 ON ASPIRIN AND CLOPIDOGREL. THE SITE REPORTED AN EVENT OF CARDIAC CHEST PAIN WITH AN ONSET OF (B)(6) 2011. THE SUBJECT WAS HOSPITALIZED ON (B)(6) 2011, 567 DAYS POST INDEX PROCEDURE, AND TREATED WITH REVASCULARIZATION TO THE TARGET VESSEL/TARGET LESION FOR THE TREATMENT OF AN 80% RESTENOSIS OF THE PROMUS STENT WITH A DRUG ELUTING STENT. TREATMENT WAS ALSO PERFORMED ON THE RIGHT CORONARY ARTERY (RCA) A NON TARGET VESSEL, FOR THE TREATMENT OF RESTENOSIS OF PREVIOUSLY PLACED NON-ABBOTT STENTS WITH THE PLACEMENT OF FOUR PROMUS STENTS. THE ATTEMPT TO CROSS WITH THE 3.0 X 15 PROMUS STENT FAILED INITIALLY; HOWEVER, AFTER ADDITIONAL PREDILATATION, WAS ABLE TO CROSS AND BE DEPLOYED. A 3.0 X 28 MM, 3.5 X 28 MM AND 3.5 X 12 MM STENTS WERE DEPLOYED OVERLAPPING THE IN THE RCA. DURING THE TREATMENT OF THE RCA, THE PATIENT WAS EXPERIENCING CHEST PAIN AND ST ELEVATION IN THE INFERIOR LEADS. THE PATIENT WAS TREATED FOR BRADYCARDIA WITH A PACEMAKER. AN INTRA AORTA BALLOON PUMP WAS PLACED AS THE PATIENT WAS MANIFESTING EVIDENCE OF HYPOTENSION. THERE WAS A NO REFLOW DUE TO EXTENSIVE ATHERO-EMBOLIZATION FROM THE STENTING OF THE MID RCA. INTERGRELLIN AND ADENOSINE WERE ADMINISTERED AND FLOW DID NOT IMPROVE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 PROMUS EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT

Patients

Seq Age Sex Outcome Treatment
1 68 YR Hospitalization| R